Journal Mobile Options
Table of Contents
Vol. 58, No. 4, 2000
Issue release date: May 2000
Oncology 2000;58:286–292

Anthracycline-Based Chemotherapy of Primary Non-Hodgkin’s Lymphoma of the Testis: The Hellenic Cooperative Oncology Group Experience

Pectasides D. · Economopoulos T. · Kouvatseas G. · Antoniou A. · Zoumbos Z. · Aravantinos G. · Tsatalas C. · Halikia A. · Nikolaides C. · Kiamouris C. · Pappa E. · Pavlidis N. · Skarlos D. · Fountzilas G. · Dimopoulos M.A.
Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Testicular non-Hodgkin’s lymphoma is an uncommon disease and its outcome following chemotherapy and/or radiotherapy has been variable. A retrospective analysis was performed on 26 patients with primary testicular lymphoma treated predominantly with anthracycline-based chemotherapy between 1984 and 1999. The patients’ median age was 60 years (range 19–82 years) with 17 (65.4%) patients being older than 60 years. Four (15.4%) patients had constitutional B symptoms. There were 11 (42.3%) patients with high grade lymphoma, 12 (46.2%) with intermediate grade, 1 (3.8%) with low grade and 2 (7.7%) were not classified. According to the Ann-Anbor staging system, 18 patients (69.2%) had early (stage I/II) and 8 (30.8%) advanced (stage III/IV) disease. Chemotherapy was administered to 24 patients including 22 patients who received anthracycline-based chemotherapy. Two stage IEA patients were treated with orchidectomy and adjuvant radiotherapy to the regional lymph nodes without systemic chemotherapy. Chemotherapy alone resulted in a complete remission (CR) in 14 (58.3%) of 24 patients and partial remission in 1 (4.2%), amounting to an overall response rate (RR) of 62.5%. Of the 5 stage I patients who had chemotherapy on an adjuvant basis, 4 (80%) had CR/no evidence of disease. Of the 11 stage II patients, 8 (72.7%) achieved CR and 1 (9.1%) PR (overall RR of 81.8%). CR was obtained in 2 (25%) of 8 stage III/IV patients. Both patients remain disease free for 26 and 65 months. Excluding the 5 stage I patients, chemotherapy resulted in a CR in 10/19 (52.6%) patients and a PR in 1/19 (5.2%), inducing an overall RR of 57.8%. The mean duration of response was 75 months (range 8–145.5+ months). After a median follow-up of 87 months (range 0.13–145.5+ months) the median survival time was 31 months (range 0.13–145.5+ months) and the median time to progression (TTP) 17 months (range 0.13–145.5+ months). The median TTP was significantly higher in early disease compared to that of advanced disease (52 vs. 3 months, p = 0.02). Of the 3 patients who relapsed following disease-free status, CNS involvement occurred in 2 stage II patients and contralateral testis involvement in 1 stage IEA, respectively. The latter remained disease free for 2 years following orchidectomy alone. The other 2 patients who relapsed did not respond to salvage chemotherapy and died. There was no significant relationship between the values of LDH and β2-microglobulin with the outcome except for ESR which was significantly related with the CR (p = 0.005) or RR (p = 0.005). In conclusion, patients with primary testicular lymphoma have a poor outcome, despite the treatment with anthracycline-containing regimens. Treatment with anthracycline-based chemotherapy is recommended in patients at early stages. In advanced disease, more intensive or investigational regimens should be considered. Because the relapse rate in the CNS and contralateral testis is quite high in most studies, prophylactic CNS treatment and radiotherapy to the other testis should be included in the management of testicular lymphoma.

Copyright © 2000 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Tapperman BS, Gospodarowicz MK, Bush RS, Brown TC: Non-Hodgkin’s lymphoma of the testis. Radiology 1982;142:203–208.

    External Resources

  2. Sussaman EB, Hajdu SI, Lieberman PH, Whitmore WF: Malignant lymphoma of the testis. A clinicopathologic study of 37 cases. J Urol 1977;118:1004–1008.

    External Resources

  3. Connors JM, Klimo P, Vass N, Fairey RN, Jackson S: Testicular lymphoma: Improved outcome with early brief chemotherapy. J Clin Oncol 1988;6:777–781.
  4. Freeman C, Berg JW, Culter JS: Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252–260.
  5. Read G: Lymphoma of the testis. Results of treatment 1960–1977. J Clin Radiol 1981;32:687–692.
  6. Economopoulos TH, Asprou N, Stathakis N, Papageorgiou E, Dervenoulas J, Xanthaki K, Raptis S: Primary extranodal non-Hodgkin’s lymphoma in adults: Clinicopathological and survival characteristics. Leuk Lymphoma 1996;21:131–136.

    External Resources

  7. Abell MR, Holtz F: Testicular and paratesticular neoplasms in patients 60 years of age and older. Cancer 1968;21:852–870.
  8. Crellin AM, Hudson BV, Bennett MH, Harland S, Hudson GV: Non-Hodgkin’s lymphoma of the testis. Radiother Oncol 1993;27:99–106.
  9. Duncan PR, Checa F, Gowing NFC, Mc Elwain TJ, Peckham MJ: Extranodal non-Hodgkin’s lymphoma presenting in the testicle. A clinical pathologic study of 24 cases. Cancer 1980;45:1575–1584.
  10. Ciato S, Cionini L: Malignant lymphoma of the testis. Acta Radiol Oncol Radiat Phys Biol 1979;18:572–576.

    External Resources

  11. Kiely JM, Massey BD, Harrison EG, Utz DC: Lymphoma of the testis. Cancer 1975;26:847–852.
  12. Buskirk SJ, Evans RG, Banks RM, O’Connell MJ, Earle JD: Primary lymphoma of the testis. Intern J Radiat Oncol Biol Phys 1982;8:1699–1703.

    External Resources

  13. Jackson SM, Montessori GA: Malignant lymphoma of the testis: Review of 17 cases in British Columbia with survival related to pathological subclassification. J Urol 1980;123:881–883.

    External Resources

  14. Paladugu RR, Bearman RM, Rappaport H: Malignant lymphoma with primary manifestation in the gonad. A clinicopathologic study of 38 cases. Cancer 1980;35:561–570.
  15. Talerman A: Primary malignant lymphoma of the testis associated with sclerosis and nodularity. Br J Urol 1977;49:23–28.

    External Resources

  16. The Non-Hodgkin’s Lymphoma-Classification Project. National Cancer Institute sponsored study of classification of Non-Hodgkin’s lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112–2135.
  17. Martenson JA, Buskirk SJ, Ilstrup DM: Patterns of failure in primary testicular non-Hodgkin’s lymphoma. J Clin Oncol 1988;6:297–302.
  18. Touroutoglou N, Dimopoulos MA, Younes A, Hess M, Pugh W, Cox J, Cabannillas F, Jarris AH: Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol 1995;11:1361–1367.
  19. Sasai K, Yamabe H, Tsutsui K, Dodo Y, Ishigaki T, Shibamoto Y, Hiraoka M: Primary testicular non-Hodgkin’s lymphoma. A clinical study and review of the literature. Am J Clin Oncol 1997;20:59–62.
  20. Turner RR, Colly TV, Macintosh FR: Testicular lymphoma: A clinicopathologic study of 35 cases. Cancer 1981;48:2095–2101.

    External Resources

  21. Kaplan EL, Meier P: Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–481.
  22. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Treat Rep 1966;50:163–170.
  23. Doll DC, Weiss RB: Malignant lymphoma of the testis. Am J Med 1986;81:515–524.

    External Resources

  24. Linassier C, Desablens B, Yves Le Prise P, Luc Harousseau J, Jacob C, Gandhour C, Lucas V, Leloup R, Escoffre M, Colombat P, Tabuteau S: Primary testicular non-lymphoblastic intermediate-high grade non-Hodgkin’s lymphoma: Results of a Goelams Prospective Study (abstract 1253). Proc of Am Soc Clin Oncol 1999;18:326.
  25. Lippuner T, Gospodarowicz M, Pintilie M, Sturgeon J, Tsang R, Zanke B: Testicular lymphomas: Pattern of failure after long-term follow-up. (abstract 234). Ann Oncol 1999;10 (suppl 3):68.
  26. Shahab N, Doll DC: Testicular lymphoma. Semin Oncol 1999;26:259–269.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50